Pharma Exclusives Pressreleases
Moderna Announces Update on Investigational Pandemic Influenza Program
Thursday, May 29, 2025Moderna Inctoday announced positive interim data from a Phase clinical study NCT evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine mRNA in approximately healthy adults aged years and older
TQ Therapeutics GmbH Announces Acquisition of Juno Therapeutics GmbH
Wednesday, May 28, 2025TQ Therapeutics GmbH TQx a biotechnology company dedicated to advancing the field of cellular therapies through innovative technologies today announced the acquisition of Juno Therapeutics GmbH Juno GmbH
DEBRA Research and Dermaliq Enter into a Strategic Collaboration to Advance Cutaneous Drug Delivery for Epidermolysis Bullosa
Wednesday, May 28, 2025DEBRA Research GmbH a global nonprofit organization dedicated to advancing research and drug development for those affected by Epidermolysis Bullosa EB and Dermaliq Therapeutics Inc a clinicalstage
Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency
Tuesday, May 27, 2025Hansa Biopharma AB Hansatoday announced that it plans to restructure the organization to optimize resource allocation and improve operational efficiency The planned restructuring would result in an approximately reduction
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
Tuesday, May 27, 2025Teva Pharmaceutical Industries Ltd and Biolojic Design Ltd Biolojic a biotechnology company using computational biology and artificial intelligence to design next generation multifunctional antibodies known as multibodies
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
Friday, May 23, 2025Roche announced today twoyear followup data from the phase III STARGLO study After a median followup of months data showed a improvement in overall survival OS for patients treated with Columvi glofitamab in combination with gemcitabine and oxalipl...
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
Friday, May 23, 2025Roche announced today a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roches recently unveiled nextgeneration sequencing NGS Sequencing By Expansion SBX technology This collaboration will focu...
Acquisition of EsoBiotec completed
Tuesday, May 20, 2025AstraZeneca today announced the successful completion of the acquisition of EsoBiotec a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity
CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing
Tuesday, May 20, 2025CellProthera a regenerative cell therapy developer specializing in ischemic diseases has chosen CELLforCURE by SEQENS as its contract development and manufacturing organization CDMO partner for its planned Phase trial for ProtheraCytes
Touchlight Wins ISPE Facility of the Year Award for Innovation, Recognised for Revolutionary dbDNA™ Manufacturing at Morelands Facility
Thursday, May 15, 2025Touchlight a pioneering leader in synthetic DNA technology is proud to announce that its Morelands Facility has been named the Innovation Winner in the prestigious International Society for Pharmaceutical Engineering ISPE
